Abridge pricing

About

Abridge is an enterprise ambient AI clinical documentation company headquartered in Pittsburgh and San Francisco. As of the July 2026 capture it positions itself as “enterprise-grade AI” and “one intelligence layer connecting health systems, payers, and life sciences organizations” — a notably wider buyer frame than the health-system-only pitch it ran earlier in 2026. The product is now described across three moments of care: pre-visit (history, open care gaps and context surfaced before the encounter), encounter (ambient capture with real-time clinical decision support and order capture), and post-visit (finalized notes, coding specificity, orders and patient summaries “ready for review, billing, and follow-up”). The site’s product navigation lists three lines: Clinicians, Nurses, and Revenue Cycle, with “Contextual Reasoning” now presented as an AI capability rather than a separate CDS module. A “NOW AVAILABLE” banner promotes context-aware evidence drawn from UpToDate, the New England Journal of Medicine and JAMA, contextualized to the encounter.

Abridge is one of the largest players in the ambient-scribe category. The site now claims it is trusted by 300+ health systems (up from the 150+ it advertised in mid-2026) and powers 100M+ conversations each year — Mayo Clinic (2,000+ physicians), Duke Health (5,000 clinicians), Johns Hopkins, Kaiser Permanente, UPMC, Northwell, UCHealth, Memorial Sloan Kettering, NYU Langone and dozens more. It reports 95% user retention and 30x adoption growth, and deep Epic integration (Epic holds an equity stake and revenue-share relationship, reported by third parties). Sacra estimates ARR around $100M by mid-2025 (up from ~$60M at end of 2024). On funding, Abridge raised a $250M Series D in February 2025 at $2.75B, a $300M Series E in June 2025 led by a16z (with Khosla) at $5.3B, and a reported $316M Series E extension in April 2026 at the same valuation — among the fastest valuation climbs in health AI. It has been named Best in KLAS in both 2025 and 2026, and on 2026-07-20 announced it had welcomed the Altrina team.

For the most current information, visit Abridge. Note: there is no public pricing page — the site routes every inquiry to Contact Us.

Pricing summary : How Abridge’s pricing model works

Abridge is fully sales-only: there is no published price list, no self-serve signup, no free tier, and no /pricing page at all — every product, CTA and nav path on the site resolves to “Contact Us.” The contact page is an email-gated multi-step quote form: step one is a single “Get in touch with us” email field with a NEXT button, and only after submitting it do the qualifying fields appear (name, organisation, EHR, role, physician-count band) — so a buyer cannot state a clinician count or budget without first handing over an email. Pricing is quoted per health-system deal. The reported structure is a per-clinician (per-seat / PEPM-style) annual license, with total contract value scaling by clinician count, encounter volume, and which product lines (Clinicians, Nurses, Revenue Cycle) the system attaches. Purchasing happens at the system or department level on annual enterprise commitments — an individual clinician cannot buy it directly.

The July 2026 capture surfaces a second contract shape alongside the per-seat license: a customer story titled “Why CHRISTUS Health Expanded to an Unlimited Enterprise Agreement with Trusted AI Partner Abridge.” An unlimited, system-wide agreement decouples price from clinician headcount entirely — it is a site-license motion layered on top of the per-clinician default, and it is the first time Abridge’s own surfaces name a non-seat-counted contract structure. Neither shape carries a published number.

Third-party trackers report an indicative per-clinician range rather than a single list price (the specific figures, and the gap between the quoted floor and reported enterprise deployments, are in Hidden costs below), positioning Abridge between lower-cost individual scribes and premium incumbents like Nuance DAX. Buyer-reported ranges run wider depending on integration depth and product mix. All such figures are third-party-reported and indicative only — Abridge does not confirm pricing publicly, and no dollar figure appears on any of its own surfaces, on any of the four pages captured.

What makes this different: unlike token- or request-metered AI tools elsewhere in this corpus, Abridge’s value metric is the clinician seat and the documentation it produces — a unit health systems already budget by provider headcount. Pricing is wrapped in a classic enterprise health-IT motion (EHR integration, security review, multi-year deal) rather than a published rate card, and the Revenue Cycle line ties some of the value to billable, coded output (“coding specificity… ready for review, billing, and follow-up”), edging toward outcome-aligned value without publishing an outcome meter. The buyer frame has also widened past providers to payers and life sciences organizations, which implies contract shapes beyond the clinician seat that Abridge has not yet described publicly.

Pricing by product

Abridge platform (product lines)

Enterprise agreements

Sales motions across products: sales-led only — email capture → demo → security/EHR review → custom quote → annual enterprise contract. No free tier, no monthly option, no self-serve, and no published rate for any line above. Third-party indicative per-clinician figures (discussed in Pricing summary) are reported, not official; treat the per-clinician number as a negotiation starting point, not a posted rate.

Hidden costs : What Abridge users actually pay

Because pricing is quoted and modular, the real cost is shaped by how many clinicians are licensed, which modules are attached, and how deep the EHR integration runs — not a published rate card. The biggest “hidden” factors health systems cite: implementation and change management (clinician training, workflow redesign, EHR build) are typically separate from the per-seat license; the revenue-cycle and nursing modules price on top of the core clinician license; and annual, multi-year commitments remove the option to pilot month-to-month at scale.

Outside the Facts table, third-party guides put a per-clinician list figure around $2,500 per year (about $208/month), and a second, independent tracker reports Abridge licenses “starting at $199 per seat per month” as of March 2025 — two floors that agree within ~5% of each other on an annualised basis. Read them as a floor, not a quote: the same tracker that carries the $2,500 figure elsewhere on the same page describes “Abridge’s enterprise pricing of $300-600/month” per clinician when contrasting it against cheaper self-serve scribes, which annualises to roughly $3,600–$7,200 per clinician per year. The honest output is therefore a reported band, not a point estimate — about $199–$208 per clinician per month at the quoted floor, rising to $300–$600 per clinician per month for full enterprise deployments — with the spread driven by integration depth and how many product lines are attached. That puts Abridge above lightweight self-serve scribes — Freed’s published ladder is $39 / $79 / $119 per clinician per month billed monthly (Starter capped at 40 notes, Core unlimited, Premier with EHR push and coding; Premier is the only tier annual billing discounts, to $104/month) — and below premium incumbents — Microsoft’s Nuance DAX / Dragon Copilot publishes no price at all, and a single third-party tracker (Sacra) puts it around $600/month, a figure Microsoft does not confirm. Treat all of these as third-party-reported and indicative, not official. Other things to budget for: a multi-year commitment is common at health-system scale; total cost is opaque until you receive a quote, making apples-to-apples comparison against per-seat alternatives hard pre-sales; and value realization depends on adoption, so clinician enablement is a real (if unbilled) cost of ownership.

Want to estimate your own Abridge bill? Use the Abridge pricing calculator to model your costs based on clinician count and module mix.

Pricing evolution : Abridge pricing history and changes

Cadence

Tracked range: 2025–present. Abridge has never published a public price list, so there are no Wayback price snapshots to chart — the evolution here is funding, scale, and product modules, not posted rate cards.

Notable changes

• 2025-02 — $250M Series D at $2.75B; reports 100+ health systems and a revenue-cycle product for billable/coded notes (FierceHealthcare). Pricing stays sales-only.
• 2025-06 — $300M Series E led by a16z (with Khosla) at $5.3B, nearly doubling valuation in four months (FierceHealthcare, TechCrunch); 150+ systems, ARR ~$100M.
• 2026-02 — Named #1 Best in KLAS for Ambient AI in Revenue Cycle for the second consecutive year.
• 2026-04 — Reported $316M Series E extension at $5.3B (a16z, Khosla, NVIDIA NVentures, Lightspeed, Bessemer reported); commercial model unchanged — negotiated per-clinician health-system contracts.
• 2026-07-20 — Abridge announces it has welcomed the Altrina team, and a keynote unveils a “Patient-Centered Clinician Intelligence Platform” — platform-level framing that matches the packaging consolidation below rather than any change in how deals are priced.
• 2026-07-22 — First non-seat contract shape published. The Customers page names an “Unlimited Enterprise Agreement” (CHRISTUS Health) alongside the per-clinician license — the first time Abridge’s own surfaces describe a contract that is not counted per clinician. Same capture: product lines consolidate from four to three (Clinicians, Nurses, Revenue Cycle) with the CDS module folded in as context-aware evidence from UpToDate, NEJM and JAMA marked “NOW AVAILABLE”; the buyer frame widens from health systems to “health systems, payers, and life sciences organizations”; and the deployed-base claim moves from 150+ to 300+ health systems. No price changed, because none is published on any of the four surfaces captured.

What’s unique : Abridge’s distinctive pricing mechanics

1. Per-clinician, not per-token — but the seat is no longer the only shape. In a corpus full of token- and request-metered AI tools, Abridge prices on the clinician seat — a unit health systems already budget by provider headcount. That keeps the meter intuitive for CMIOs and CFOs but ties revenue to clinician count rather than the volume of AI work done. As of the 2026-07-22 capture there is a second, named alternative: an unlimited enterprise agreement (CHRISTUS Health) that removes headcount from the invoice entirely. A vendor that adds a site-license escape hatch to its own per-seat default is telling you where the seat metric strains — at systems whose adoption is growing faster than their provider count.

2. Fully gated — no /pricing page at all. Most sales-only vendors at least keep a /pricing URL with a contact form; Abridge routes every path to “Contact Us.” Nothing is published, which maximizes negotiating leverage for an enterprise health-IT sale and keeps competitors guessing.

3. EHR integration as the moat behind the price. Pricing is wrapped in deep Epic (and multi-EHR) integration with reported equity/revenue-share ties to Epic. The switching cost isn’t the per-seat fee — it’s the embedded EHR workflow, which is what lets Abridge sell annual, multi-year, system-wide contracts rather than month-to-month seats.

4. Packaging that consolidates instead of proliferating. Most AI vendors add SKUs as they add capability; the July 2026 capture shows Abridge doing the opposite — four product lines became three, and the CDS module was absorbed into the platform as context-aware evidence (UpToDate, NEJM, JAMA) marked “NOW AVAILABLE” rather than sold as an attachable add-on. That removes a paid attach point, which is a revenue sacrifice unless the included capability raises what the remaining lines command. It reads as a deliberate trade: fewer things to quote and negotiate line-by-line, in exchange for a bigger, harder-to-unbundle platform price — the same logic that makes the unlimited agreement possible.

Strengths & weaknesses

Billing UX : Abridge billing controls and transparency

• Billing controls — Enterprise contract-based: annual (often multi-year) commitments, no self-serve plan changes, no monthly billing. Seat counts and product-line changes go through the account team and contract amendments rather than an in-app toggle. The only self-serve control on the whole site is the Log In button and the Contact Us email-capture form.
• Analytics & Reporting — named as an enterprise-grade capability on the Clinicians page: “Track and monitor Abridge usage across your entire health system.” This is the closest thing to a consumption meter Abridge exposes, and it is an adoption/utilization view for IT and CMIO teams, not a spend or invoice view.
• Custom Governance Control — a named control that lets a system “customize Abridge to fit your compliance and governance” — the entitlement/policy layer of the contract, configured at the system level rather than per clinician.
• Single Sign-On — named control to “control access and make it easy for your clinicians to use Abridge”; SSO is the practical mechanism by which licensed seats are provisioned and de-provisioned.
• Security posture bundled into the license — 256-bit encryption in transit and at rest, US-based secure data centers, and HIPAA-compliant enterprise-grade security are presented as included in every enterprise agreement rather than as a paid compliance tier — a notable contrast with the SaaS norm of gating SSO and audit behind an Enterprise upsell.
• Impact Calculator — a public ROI tool linked in the site footer under Resources. It models clinical/operational impact, not cost; there is still no public cost calculator and no published rate card, so health systems cannot model spend without a sales conversation.
• Payment options — Invoiced annual enterprise contracts via direct sales, scoped to the system’s clinician count, product lines, and EHR integration — or, in at least one publicly named case (CHRISTUS Health), an unlimited enterprise agreement that removes headcount from the invoice entirely. Implementation and enablement services are typically separate line items.

Strategic wins : Why Abridge’s pricing decisions worked

1. Pricing on a metric health systems already trust

Anchoring on the clinician seat lets Abridge sell into provider budgets organized by headcount, sidestepping the “what’s a token?” education problem that pure-usage AI tools face. See how AI companies structure pricing.

2. Two expansion paths instead of one

Selling Clinicians, Nurses and Revenue Cycle as separate lines creates the classic land-and-expand path — start with physician documentation, add nursing and revenue cycle later — growing contract value without renegotiating the core seat license. The 2026-07-22 capture adds a second, orthogonal path: the unlimited enterprise agreement named in the CHRISTUS Health story lets a saturating account convert from counting seats to buying system-wide access. That matters because the two paths fail at different times — line attach runs out once a system owns all three, while the seat count runs out once every clinician is licensed. Having both means an account that has stopped growing on one axis can still grow on the other. Related: outcome-based pricing trends.

3. EHR integration as the durable lock-in

By embedding deep into Epic and other EHRs (with reported equity/revenue-share ties to Epic), Abridge turns the documentation workflow into the switching cost — letting it command annual, system-wide contracts at premium per-clinician rates. See choosing the right usage metric.

Areas to improve : Gaps in Abridge’s pricing approach

1. Zero pricing transparency

No /pricing page and no published rate card force every buyer into a sales motion just to learn rough cost. The July 2026 capture makes this gap wider, not narrower: there are now two contract shapes a buyer could be quoted — per-clinician or unlimited — and Abridge publishes no price, no qualifying threshold, and no eligibility criteria for either. A CMIO cannot tell from the site whether their system is a seat deal or a site-license deal, which is the first question that determines the budget. Even a posted “starting at,” or simply naming the size at which the unlimited agreement becomes available, would reduce friction for the many health systems now comparing ambient scribes head-to-head. See bill shock and cost unpredictability.

2. Seat metric vs. automation thesis

As AI documentation does more of the work, a per-clinician seat fee can feel disconnected from the actual volume of notes, encounters, and coded output produced. The 2026-07-22 unlimited enterprise agreement is the first evidence Abridge feels this itself — but a site license answers the problem by removing the meter rather than by fixing it, so price still tracks negotiating position instead of work done. An outcome- or encounter-aligned meter (notes generated, billable codes captured) would keep price and value aligned as the product scales; publishing the criteria that move a system from seats to unlimited would at least make the fork navigable.

3. High floor blocks smaller buyers

The enterprise-only motion (annual, multi-year, system-wide) shuts out small practices and individual clinicians, who are served instead by self-serve scribes like Freed. A lighter, published SKU for small groups would widen the funnel without undermining the health-system motion.

Key takeaways

1. Abridge publishes nothing — pricing is fully sales-only. There is no /pricing page at all; expect a negotiated per-clinician (per-seat / PEPM-style) annual contract scaled by clinician count and the product lines you attach.
2. The value metric is the clinician seat — and the reported price is a band, not a number. Two independent third-party trackers (Sacra, Contrary Research) agree on a starting rate near $199–$208 per clinician per month (~$2,500 per clinician per year), while the same tracker that publishes that list figure separately puts enterprise deployments at $300–$600 per clinician per month. Treat the floor as a floor; every figure is third-party-reported and indicative only — Abridge confirms none.
3. Annual, enterprise-only, no free tier. Purchasing happens at the health-system level on multi-year commitments — there is no self-serve or individual-clinician path.
4. Ask which contract shape you’re being quoted. Since July 2026 Abridge names two: the per-clinician license and an unlimited enterprise agreement (CHRISTUS Health) that drops headcount from the invoice. Three lines still price separately, so identical clinician counts can cost very differently depending on both what’s attached and which shape you land in.
5. EHR integration is the moat. Deep Epic integration (with reported equity/revenue-share ties) is what lets Abridge hold premium, sticky, system-wide contracts.

UBP implications

1. Seat-based is durable where buyers budget by headcount, but it ages awkwardly when the product’s job is to automate the documentation work — every ambient-scribe vendor will eventually face pressure toward encounter- or outcome-aligned meters. Abridge’s July 2026 unlimited enterprise agreement shows the likelier near-term escape valve is not a better meter but no meter: at saturated accounts the seat count stops moving, and a site license converts that ceiling into a renegotiation. See usage-based pricing strategy.
2. Full opacity is a deliberate enterprise choice, trading shorter sales cycles for negotiating leverage; it works at high ACV with deep EHR integration but blocks the bottom-up adoption that powers self-serve competitors.
3. The Revenue Cycle line hints at outcome alignment — billing on billable/coded output is closer to value than a flat per-seat fee, and is the most likely path by which ambient-scribe pricing evolves from seats toward outcomes. The July 2026 widening of the buyer frame to payers and life sciences organizations points the same way: neither buys clinician seats, so serving them forces a value metric that isn’t the provider headcount.

Sources

• Abridge official website (accessed 2026-07-22)
• Abridge — Clinicians platform (accessed 2026-07-22)
• Abridge — Customers (accessed 2026-07-22)
• Abridge — Contact (no /pricing page; email-capture form only) (accessed 2026-07-22)
• Abridge — Series E announcement (company blog) (accessed 2026-06-10)

Third-party trackers and press are not listed here: Abridge publishes no prices, so every indicative figure on this page is cited inline where the claim is made. The indicative per-clinician figures were re-checked against their sources on 2026-07-22 — Sacra and Contrary Research for the Abridge band, and Freed’s own pricing page for the self-serve comparison anchor.

Bottom line

Abridge is an a16z-backed ($5.3B valuation) enterprise ambient-AI clinical documentation company — real-time, EHR-integrated notes for clinicians, nursing, and revenue cycle, deployed at a claimed 300+ health systems including Mayo, Duke, and Johns Hopkins. Its pricing is fully sales-only with no public list and no /pricing page (the site routes everything to Contact Us): the default is a negotiated per-clinician (per-seat / PEPM-style) annual contract, scaled by clinician count, encounter volume, and which of the three product lines are attached. Third parties cite a band rather than a price — a quoted floor near $199–$208 per clinician per month ($2,500 per clinician per year) rising to a reported $300–$600 per clinician per month on full enterprise deployments — indicative only, never confirmed by Abridge. As of July 2026 a second shape is named on Abridge’s own surfaces: an unlimited enterprise agreement (CHRISTUS Health) that removes headcount from the invoice — the clearest sign yet that the seat metric strains at saturated accounts. The open question is no longer whether the per-clinician model bends but what replaces it: a site license that abandons the meter, or the encounter/outcome meter that the Revenue Cycle line and the new payer and life-sciences buyers both point toward. Browse the pricing blueprint for more fully-researched company profiles.

Want to compare Abridge against other healthcare and AI-documentation companies? Browse the pricing blueprint.

Pricing timeline : Major events on a vertical axis

Each milestone below corresponds to a public pricing change, product launch, or material adjustment. Major events use a filled marker; minor adjustments use a faded one.

Unlimited enterprise agreement named; product lines consolidate 4 to 3

Jul 2026

Abridge's own surfaces name a second contract shape for the first time — an 'unlimited enterprise agreement' (CHRISTUS Health) that decouples price from clinician headcount, sitting alongside the per-clinician license. Product lines consolidate from four to three (Clinicians, Nurses, Revenue Cycle) as the CDS module folds into the platform as context-aware evidence from UpToDate, NEJM and JAMA. The buyer frame widens from health systems to 'health systems, payers, and life sciences organizations' and the deployed-base claim moves from 150+ to 300+ health systems. Still no published price on any surface.

Series E extension — reported $316M at $5.3B

Apr 2026

Abridge closes a reported $316M Series E extension at a $5.3B valuation (a16z, Khosla, NVIDIA NVentures, Lightspeed, Bessemer reported). Scale and Epic integration deepen; pricing stays sales-only and negotiated per health-system deal.

Series E — $300M at $5.3B, ARR ~$100M, 150+ systems

Jun 2025

Four months after Series D, Abridge raises a $300M Series E led by a16z (with Khosla), nearly doubling its valuation to $5.3B. Deployed at 150+ health systems with ARR reported around $100M. Commercial model unchanged: per-clinician enterprise contracts, no public price list.

Series D — $250M at $2.75B, 100+ health systems

Feb 2025

Abridge raises a $250M Series D, reaching a $2.75B valuation, and reports deployment across 100+ health systems alongside a new revenue-cycle product for billable notes. Pricing remains sales-only and enterprise-negotiated — no public list price introduced.